All products are sold strictly for laboratory research use only. Not for human or veterinary consumption, diagnosis, or treatment. Not approved by the FDA.

Research Use Only

Search results for "BPC-157"

Found 10 products

10 results

Sort by:

Thymosin Alpha-1

Thymosin Alpha-1

28-Amino Acid Immunomodulator: N-terminal fragment of prothymosin alpha (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN), originally isolated from thymus 1977, 3,000+ publications, thymalfasin (Zadaxin) approved in 35+ countries
Pleiotropic Immune Activation: TLR2/3/4/7/9 agonist, dendritic cell activation, T-cell maturation (CD4+/CD8+), Th1 polarization (IL-2/IL-12/IFN-γ↑), NK cell enhancement, PD-1/Tim-3 exhaustion marker reduction
Clinical Status: FDA orphan drug (DiGeorge anomaly, melanoma, hepatitis B, HCC), China approved for hepatitis B/HCC, COVID-19 mortality reduction (11.11% vs 30.00%, Liu et al. 2020), sepsis meta-analysis 41% mortality reduction

$49.00

Semax 30mg

Semax 30mg

ACTH(4-10) Analogue: Heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, developed 1982 Russian Academy, ACTH(4-7) + Pro-Gly-Pro extension for metabolic stability, 800+ publications, no hormonal activity
Multi-Modal Neuroprotection: BDNF upregulation (1.4× protein, 3× mRNA hippocampus), monoamine modulation (180% 5-HIAA), copper chelation (K_D 1.3×10⁻¹⁵ M), anti-amyloid activity, transcriptomic ischemia protection
Clinical Status: Russian FDA approved, List of Vital & Essential Drugs 2011, Phase I-II trials 1990-1996, extensive clinical use for stroke/cognitive disorders/optic neuropathy, low toxicity profile

$30.00

Selank 10mg

Selank 10mg

Synthetic Tuftsin Analogue: Heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro, developed Russian Academy of Sciences, tuftsin core + Pro-Gly-Pro extension for metabolic stability, 20+ years research
Multi-Modal Mechanism: Positive allosteric modulator of GABA-A receptors, upregulates BDNF (hippocampus/cortex), inhibits enkephalinase (IC50 15 μM), modulates monoamines, no tolerance/dependence
Clinical Status: Russian FDA approved 2009 for GAD/neurasthenia (intranasal 0.15%), RCT showed efficacy equal to medazepam with additional nootropic effects, no sedation/amnesia unlike benzodiazepines

$40.00

PT-141 10mg

PT-141 10mg

FDA-Approved Melanocortin Agonist: Cyclic heptapeptide MC3R/MC4R agonist, approved June 2019 (Vyleesi) for premenopausal HSDD, 100+ publications, first melanocortin therapeutic for sexual function
CNS Mechanism: Crosses blood-brain barrier, activates hypothalamic MC4R in mPOA triggering dopamine release, melanocortin-dopamine integration, mesolimbic reward pathway modulation
Clinical Development: 43 completed trials with 3,500+ subjects, Phase 3 RECONNECT (n=1,267) showed +0.35 desire improvement, 58% vs 36% responder rates, well-characterized safety profile

$33.25

KLOW (80mg)

KLOW (80mg)

Quad-Peptide Blend: BPC-157 10mg + TB-500 10mg + GHK-Cu 50mg + KPV 10mg (80mg total)
Enhanced Anti-Inflammatory: KPV addition for NF-κB pathway inhibition and cytokine control
Comprehensive Regeneration: Cytoprotection, angiogenesis, collagen synthesis, and inflammation modulation

$110.00

GLOW BLEND (50mg)

GLOW BLEND (50mg)

Triple-Peptide Blend: BPC-157 + TB-500 + GHK-Cu for comprehensive tissue regeneration
Multi-Phase Coverage: Inflammation, angiogenesis, cell migration, and matrix remodeling
Research Formulation: 50mg total, ≥98% purity per component, lyophilized powder

$97.00

BPC-157

BPC-157

Gastric Pentadecapeptide: 15-amino acid sequence (GEPPPGKPADDAGLV), ≥99% purity, 4-pack format
NO System Modulation: VEGFR2-Akt-eNOS and Src-Caveolin-1-eNOS pathway research
Tissue Repair Studies: FAK-paxillin pathway activation and angiogenic signaling

$200.00

$150.00

BPC-157 / TB500 (5 mg / 5 mg)

BPC-157 / TB500 (5 mg / 5 mg)

BPC-157 5mg / TB-500 5mg research blend for laboratory studies
Pharmaceutical-grade dual peptide for in-vitro research only
Not for human consumption

$70.00

KLOW

KLOW

Advanced Quad-Peptide Research Formulation: BPC-157 10mg + TB-500 10mg + GHK-Cu 50mg + KPV 10mg (80mg total), extends GLOW Blend with KPV for enhanced inflammation modulation
Comprehensive Repair Cascade: BPC-157 (cytoprotection, VEGFR2 activation), TB-500 (cell migration, angiogenesis), GHK-Cu (collagen synthesis, 4,000+ gene modulation), KPV (NF-κB inhibition, anti-inflammatory signaling)
KPV Anti-Inflammatory Mechanism: C-terminal tripeptide of α-MSH, NF-κB pathway inhibition, TNF-α/IL-1β/IL-6 suppression, NO melanotropic effects (lacks melanocortin core sequence required for MC1R activation)

$110.00

Inflammation Defense Protocol - BPC-157 TB-500 MOTS-c Package

Inflammation Defense Protocol

BPC-157, TB-500, and MOTS-c bundled together for comprehensive recovery research

$0.00